The clinical and radiological observation of endoscopic retrograde cholangiopancreatography

1981 ◽  
Vol 17 (3) ◽  
pp. 492
Author(s):  
C S Park ◽  
B L Park ◽  
H W Chun ◽  
B G Kim
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Endoscopic Retrograde

Endoscopic retrograde cholangiopancreatography (ERCP) in patients aged more than 90 years: A single Center experience

2017 ◽  
Vol 55 (05) ◽  
pp. e28-e56
Author(s):  
P Dinkhauser ◽  
D Hubner ◽  
B Stadler ◽  
W Kranewitter ◽  
R Nömeyer ◽  
...  
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Single Center ◽  
Endoscopic Retrograde ◽  
Single Center Experience

Efficacy of octreotide (Octrade) for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

2020 ◽  
Vol 1 (30) ◽  
pp. 30-36
Author(s):  
E. A. Krylova ◽  
D. V. Aleinik
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Intravenous Infusion ◽  
Pancreatic Enzyme ◽  
Enzyme Secretion ◽  
Continuous Intravenous Infusion ◽  
Endoscopic Retrograde ◽  
Pancreatic Enzyme Secretion

The article presents the results of a study of the effectiveness of the use of an inhibitor of pancreatic enzyme secretion of octreotide (Octrade) for the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). It was shown that the administration of Octrade at a dose of 0.3 mg in 500 ml of 0.9 % NaCl by continuous intravenous infusion for 7 hours and then 0.1 mg of Octrade subcutaneously at 6 and 12 hours after the end of intravenous infusion significantly reduced the frequency of pancreatitis (4.0 % and 22.2 %; p < 0.05) and hyperamylasemia (8.0 % and 25.9 %; p < 0.05) after ERCP. It is concluded that Octrade is effective in preventing the development of pancreatitis and hyperamilasemia after ERCP.

Sign in / Sign up

Export Citation Format

Share Document